文献速递肝病

肝细胞微泡水平改善肝硬化患者死亡预测

Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.
PubMed 文献 · Hepatology · 2018-05-21

研究前瞻性纳入两个中心2013至2015年接受肝导管检查的严重纤维化或肝硬化患者,检测循环微泡水平。肝细胞微泡水平在Child-Pugh C级患者中分别比A级和B级高4.0倍和2.2倍,与肝静脉压力梯度相关但不能识别HVPG≥10 mm Hg;肝细胞微泡>65 U/L可独立于Child-Pugh评分和MELD预测6个月死亡,并在验证队列中确认。

要点

  • 肝细胞微泡水平在Child-Pugh C级分别比A级和B级高4.0倍和2.2倍。
  • 肝细胞微泡水平与HVPG相关,但不能识别HVPG≥10 mm Hg的患者。
  • 肝细胞微泡>65 U/L可独立于Child-Pugh评分和MELD预测6个月死亡。

核心结论

  • 循环微泡水平不能识别HVPG≥10 mm Hg的患者。
  • 肝细胞微泡水平强烈改善晚期慢性肝病患者6个月死亡的预测。
  • 与循环肝细胞微泡水平降低相关的治疗可能是严重肝硬化患者有吸引力的策略。

研究设计与样本

  • 前瞻性纳入2013至2015年在两个中心接受肝导管检查的严重纤维化或肝硬化患者。
  • 检测循环中膜联蛋白V+、血小板、白细胞、内皮和肝细胞微泡水平。
  • 测试队列包括139例患者,验证队列包括103例患者。

主要发现

  • 肝细胞微泡水平在Child-Pugh C级患者中分别比Child-Pugh A级和B级患者高4.0倍和2.2倍。
  • 其他微泡亚群水平不受肝病严重程度影响。
  • 肝细胞微泡水平与HVPG相关,但不能识别HVPG≥10 mm Hg的患者。
  • 肝细胞微泡水平>65 U/L独立于Child-Pugh评分和MELD预测6个月死亡。
  • 肝细胞微泡>65 U/L且MELD>15的患者6个月死亡率高于其他患者(23% vs 3%;P=0.001)。

关键数值与推荐

  • 肝细胞微泡水平>65 U/L作为预测6个月死亡的阈值。
  • 肝细胞微泡>65 U/L且MELD>15的患者6个月死亡率为23%,其他患者为3%(P=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Microvesicles (MVs) are extracellular vesicles released by cells following activation or apoptosis. Some MV subpopulations augment with cirrhosis severity and contribute to portal hypertension. This study aimed at determining if plasma MV levels can estimate the presence of hepatic venous pressure gradient (HVPG) ≥10 mm Hg and predict mortality in patients with advanced chronic liver disease. All patients with severe fibrosis or cirrhosis undergoing liver catheterization between 2013 and 2015 at two centers were prospectively included. We measured circulating levels of annexin V+ , platelet, leukocyte, endothelial, and hepatocyte MVs. The test cohort included 139 patients. Hepatocyte MV levels were 4.0-fold and 2.2-fold higher in patients with Child-Pugh C than in those with Child-Pugh A or B liver disease, respectively. Levels of other MV subpopulations were not influenced by liver disease severity. Hepatocyte MV levels correlated with HVPG but could not identify patients with HVPG ≥10 mm Hg. Hepatocyte MV level >65 U/L predicted 6-month mortality independently of Child-Pugh score and of Model for End-Stage Liver Disease (MELD). Patients with hepatocyte MV levels >65 U/L and MELD >15 had a higher 6-month mortality than other patients (23% versus 3%; P = 0.001). These findings were confirmed in a validation cohort including 103 patients. CONCLUSION: Circulating MV levels cannot identify patients with HVPG ≥10 mm Hg; by contrast, hepatocyte MV levels strongly improve prediction of 6-month mortality in patients with advanced chronic liver disease; therapies associated with decreased levels of circulating hepatocyte MV might be attractive strategies in patients with severe cirrhosis. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Payancé A, Silva-Junior G, Bissonnette J, et al. Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology. 2018. PMID: 29603327. doi:10.1002/hep.29903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。